Skip to main content

Table 4 Patients achieving at least an MID improvement, a less than MID improvement/no change or with deteriorating QoL at Week 52

From: Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life

Week 52

AQLQ Population

n (%)

SAL/FP

n = 158

FOR/BUD

n = 155

Deterioration in QoL (<0)

14 (9)

29 (19)

No Change/Improvement <MID (≥ 0 – <0.5)

32 (20)

26 (17)

At Least MID Improvement in QoL (≥ 0.5)

112(71)

100 (64)

  1. AQLQ = Asthma Quality of Life Questionnaire; FOR/BUD = formoterol/budesonide combination ; SAL/FP = Salmeterol/fluticasone propionate combination; QoL = Quality of Life; MID = minimally important difference.